CSTL vs HPP Comparison

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

Hudson Pacific Properties Inc is a vertically integrated real estate investment trust offering end-to-end real estate solutions for dynamic tenants in the synergistic, converging and secular growth industries of tech and media. It acquires, repositions, develops and operates sustainable high-quality office studio properties in high-barrier-to-entry tech and media epicenters. Its primary investment markets include Los Angeles, the San Francisco Bay Area, Seattle, New York and Vancouver, British Columbia. Its segments include Office properties and related operations and Studio properties and related operations. The majority of the revenue is derived from Office properties and related operations segment.